Front. Med. DOI 10.1007/s11684-017-0542-7

REVIEW

Normoalbuminuric diabetic kidney disease Chao Chen*, Chang Wang*, Chun Hu, Yachun Han, Li Zhao, Xuejing Zhu, Li Xiao, Lin Sun (

✉)

Department of Nephrology, Second Xiangya Hospital, Central South University, Changsha 410011, China

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2017

Abstract Diabetic kidney disease (DKD) is one of the primary causes of end-stage renal disease (ESRD). Early diagnosis is very important in preventing the development of DKD. Urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) are widely accepted as criteria for the diagnosis and clinical grading of DKD, and microalbuminuria has been recommended as the first clinical sign of DKD. The natural history of DKD has been divided into three stages: normoalbuminuria, microalbuminuria, and macroalbuminuria. However, this clinical paradigm has been questioned recently, as studies have shown that a portion of diabetes mellitus (DM) patients with normoalbuminuria have progressive renal insufficiency, referred to as normoalbuminuric diabetic kidney disease (NADKD) or nonalbuminuric diabetic nephropathy. Epidemiologic research has demonstrated that normoalbuminuric diabetic kidney disease is common, and the large number of NADKD patients suggests that the traditional paradigm needs to be shifted. Currently, the pathogenesis of NADKD remains unclear, but many clinical studies have identified some clinical and pathological features of NADKD. In addition, the long-term outcomes of NADKD patients remain controversial. In this article, we reviewed the latest studies addressing the pathogenesis, pathology, treatment and prevention of NADKD. Keywords

diabetes; diabetic kidney disease; normoalbuminuria; renal impairment

Introduction Diabetic nephropathy (DN) is the most common microvascular complication of diabetes mellitus (DM) [1] and the cause of almost half of all new cases end-stage renal disease (ESRD) in the US [2,3]. In 2007, the concept of diabetic kidney disease (DKD) was first proposed by the American Kidney Foundation [4]. The general progression of DKD starts with increasing urinary albumin excretion rate (UAER), leading to severe proteinuria, reduced estimated glomerular filtration rate (eGFR), and ESRD. Therefore, UAER or the urinary albumin to creatinine ratio (UACR) is the most important criterion for early diagnosis for DKD [5]. However, some DM patients with renal insufficiency (eGFR < 60 ml/(min$1.73 m2)) have normal-range proteinuria. In 1994, Tsalamandria and colleagues [6] first described DM patients who exhibited no clinically significant proteinuria but had renal insufficiency (eGFR < 60 ml/(min$1.73 m2)) and progressed to DKD, a

condition described as normoalbuminuric diabetic kidney disease (NADKD), nonalbuminuric diabetic nephropathy or diabetic kidney disease without albuminuria [7–10]. The latest DKD diagnostic criteria proposed by the American Diabetes Association (ADA) in 2015 include UAER>30 mg/24h or eGFR < 60 ml/(min$1.73 m2) [11], reflecting the fact that a portion of DM patients have normal-range albuminuria with renal insufficiency, which meets the criteria for DKD. Based on the concepts described by Zelmanovitzde [12] in 1997 and other sources [7,13–16], we propose the following diagnostic criteria for NADKD: (1) conformance to the latest World Health Organization (WHO) or American Diabetes Association (ADA) diagnostic criteria of diabetes; (2) eGFR < 60 ml/(min$1.73 m2); (3) urine protein excretion rate < 20 µg/min at least twice within six months, random urine protein < 17 mg/L, UAER < 30 mg/24 h (under normal use of antihypertensive drugs), or UACR < 30 mg/g; (4) exclusion of other secondary kidney diseases.

Received December 20, 2016; accepted April 26, 2017 Correspondence: [email protected]

Epidemiology of NADKD

*

The prevalence of patients with type 2 diabetes mellitus

These authors contributed equally to this article.

2

Advances in NADKD

ranges from 25% to 50% in different studies and counties [12,17–20], and the prevalence of NADKD is not low (Table 1) [7,9,13,17,20–23]. Over 15 years of follow-up (1977–1991), the UK Prospective Diabetes Study (UKPDS) found that 28% of type 2 DM patients had NADKD, whereas just 38% of DM patients developed proteinuria [17]. The third study by the National Health and Nutrition Examination Survey (NHANES III) in 2003 showed that the prevalence of NADKD was 14.29% (n = 171/1197) in type 2 DM patients [21]. The Renal Insufficiency and Cardiovascular Events (RIACE) research group found that, among type 2 DM patients with chronic kidney disease (CKD) stages 3–5, 21.66% (393/1814) had no proteinuria, and 29.71% (539/1814) had proteinuria [24]. In addition, another group reported that, among 5072 DM patients, 31% had CKD stages 3–5, and 63% had normoalbuminuria [22]. A study by Giuseppe [20] also revealed that, among 2959 DM patients with renal dysfunction, 1673 (56.6%) were normoalbuminuric, with 912 (30.8%) and 374 (12.6%) patients presenting with microalbuminuria and proteinuria, respectively. Boronat et al. [23] reported that 21.8% of DKD patients have normoalbuminuria, 20.5% have microalbuminuria, and 57.7% have severe proteinuria. The Developing Education on Microalbuminuria for Awareness of Renal and Cardiovascular Risk in Diabetes (DEMAND) study reported that 17.2% (1044/6072) of patients with CKD stages 3–5 had NADKD [13], and in a study by Mottl et al. [9], NADKD accounted for 77.3% of the cases. Furthermore, the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Compli-

cations Study (DCCT/ EDIC) showed that in type 1 DM patients who developed to eGFR < 60 ml/(min$1.73 m2), 22.47% (20/89) had UAER < 30 m/24 h [25]. Evidently, NADKD is one of the main manifestations of DKD, but the prevalence varies across studies, potentially due to the different methods for measuring proteinuria or previous treatments to alleviate proteinuria. Treatment with reninangiotensin-aldosterone system (RAAS) blockers may reduce or eliminate the incidence of urinary protein [26]. Moreover, the prevalence of NADKD varies by race. Thomas et al. [19] found that the burden of NADKD is much higher in Caucasian populations than among indigenous Australian and Asian populations; of 506 NADKD patients, 91% were Caucasian, while 2% were Indigenous Australian, and 7% were Asian. Morbidity also varies by country and region. Compared to DKD patients with UAER>30 mg/24h, the proportion of women was significantly higher than that of men among NADKD patients. A multicenter study conducted by Molitch and colleagues [25] with follow-up over 19 years showed that 89 patients with type 1 DM developed an eGFR < 60 ml/(min$1.73 m2); of those, 20 (22.47%) had AER < 30 mg/d, and 81% (17/21) were women, but in the microalbuminuria (30–300 mg/d) group (14/89) and the macroalbuminuria (>300 mg/d) group (54/89), 64.3% (9/14) and 51.85% (28/54) were women. The gender differences might relate to the lower glomerular filtration rate in women compared to men [27]. A meta-analysis study found that men with CKD of various etiologies show a more rapid decline in renal function than women, but in the NADKD group, the loss of

Table 1 Prevalence of normoalbuminuric diabetic kidney disease Low GFR participants with Percentage of patients with GFR<60 Normo (%) Micro (%) Macro (%) ml/(min$1.73 m2) 16% 28% NA NA

Author

Total (n)

Diabetes type

GFR method

Retnakara et al. [17]

7462

2

CKD-EPI otherwise

Kramer et al. [21]

9737

2

CKD-EPI otherwise

12.3%

36%

45%

19%

New et al. [22]

162 113

2

CKD-EPI otherwise

3%

63%

NA

NA

Boronat et al. [23]

78

2

CKD-EPI otherwise

100%

22%

20%

58%

Dwyer et al. [13]

11 573

2

CKD-EPI otherwise

22.3%

20.5%

30.7%

35%

Mottl et al. [9]

21 366

2

CKD-EPI equation

13.1%

52%

48%

NA

Giuseppers et al. [20]

15 773

2

CKD-EPI otherwise

37.5%

56.5%

30.8%

12.6%

Maclsaac et al. [7]

625

2

CKD-EPI otherwise

36%

39%

35%

26%

GFR, glomerular filtration rate; NA, not available.

Chao Chen et al.

eGFR in women was even faster than in men [6,28]. This may be related to female hormone levels, as reported by Porrini et al. [29]. However, the effect of hormones on renal disease in women is controversial. Several studies investigating the role of female hormones through animal models have yielded opposite results; in type 1 DM, 17βestradiol could regulate signaling of transforming growth factor β to protect women from accelerated decline in renal function [30]. However, a few studies have indicated that estrogen may have contradictory effects [31] on GFR among women with diabetes.

Pathophysiology of NADKD The microangiopathy typically observed in DKD patients with albuminuria is not common in NADKD patients. In their study, An et al. [32] found that the percentage of patients with retinopathy was 16% (7/44) in the NADKD group, whereas it was 56% (28/50) and 81% (46/57) in the microalbuminuria group and the macroalbuminuria group, respectively [32]. Similarly, Kramer and colleagues [21] found an incidence of retinopathy of 28% in NADKD patients, compared to 45% in the microalbuminuria group. Moreover, some studies have shown that macroangiopathy is more prevalent in NADKD patients. A clinical study by Boronat et al. [23] with 78 DKD patients found that in the NADKD group, 47.1% (8/17) had coronary heart disease, and 52.9% (9/17) had apparent retinopathy; however, in the albuminuria group, the prevalence of coronary heart disease was only 29.5% (18/61), and the prevalence of retinopathy reached 59.0% (36/61). It is believed that NADKD may be not directly related to microangiopathy [7,33]. Further studies have shown that eGFR decreases in type 2 diabetes patients and is associated with increases in carotid intimal-medial thickness, carotid stiffness, and the intrarenal arterial resistance index [34]. It has been reported that compared to DM patients with eGFR>60 ml/(min$1.73 m2), those with eGFR < 60 ml/(min$1.73 m2) had a higher renal artery resistance index independent of albuminuria [34,35], indicating that renal vascular lesions may be involved in the pathogenesis of NADKD. Boeri et al. [36] conducted a study of 30 DM patients in which they measured the resistive index of the interlobar arteries and found that intrarenal arteriosclerosis was mainly responsible for kidney function impairment in type 2 DM patients, without affecting the albumin excretion rate. This suggested that GFR decline in type 2 DM patients is partly due to increasing arteriosclerosis. In addition, cardiovascular disease and metabolic syndrome are associated with NADKD, as there is a positive correlation between the prevalence of NADKD and those conditions [14,37]. Lam et al. [38] demonstrated that the association between cholesterol-lowering therapy

3

and renal function progression in type 2 DM is independent of the albumin excretion rate. These studies provided clinical evidence for the role of macroangiopathy in the development of NADKD patients, which may contribute to the development of renal dysfunction in NADKD [35]. RAAS blockers are a traditional class of drugs for reducing proteinuria in DKD patients. Clinical research has shown that most NADKD patients had used a RAAS blocker [7]. Recent evidence suggests that once NADKD patients stop using the RAAS blockers, they progress to microalbuminuria [39]. An and colleagues [32] observed 151 DKD patients with renal insufficiency before treatment with RAAS inhibitors and reported the proportion of normoalbuminuria, microalbuminuria, and proteinuria at 29.1%, 33.1%, and 37.8%, respectively; however, after treatment with a RAAS inhibitor, the proportions were 35.3%, 41.2%, and 23.5%. The Nephrologic Diabetes Complications Trial (BENEDICT) included 1204 type 2 DM patients divided into two groups; 5.8% (35/601) of patients developed microalbuminuria in the angiotensin converting enzyme (ACE) inhibitor treatment group, compared to 10.9% (66/603) in the control group [40]. These results indicated that ACE inhibitors can reduce microalbuminuria and prevent the progression of DM. Recently, Porrini et al. [29] proposed that progression to NADKD might be partly due to treatment with RAAS blockers in patients with DM, which can reduce proteinuria but not improve the GFR. Thus, we should pay more attention to the relationship between RAAS inhibitors and NADKD. The tubulointerstitium is composed of tubular epithelium, vascular structures, and interstitium and accounts for 90% of renal tissue [41]. The classical interstitial pathological changes in diabetic nephropathy [42] include tubular basement membrane thickening, interstitial fibrosis, tubular atrophy, and arteriosclerosis. Lane et al. [43] found that interstitial expansion is independently associated with decreased renal function in type 1 DM. Another study demonstrated that interstitial fibrosis contributes to further renal function decline compared to glomerular injury, and this decline was independent of albuminuria [44]. This suggested that declining of eGFR is partly related to interstitial injury in type 2 DM. Further studies in NADKD patients had similar results. Ekinci et al. [39] found that 3 in 8 (37.5%) NADKD patients had interstitial and vascular lesions by renal biopsy, and only 1 in 23 (4.3%) proteinuria patients had interstitial and vascular lesions. This suggested that tubulointerstitial damage may be involved in the development of NADKD. Given the importance of renal interstitial damage in NADKD patients, it is necessary to not only detect renal function decline in a timely fashion but also to detect tubular injury. Previous studies have confirmed that TNFα and other inflammatory cytokines are involved in the DKD immune

4

and inflammatory response [45]. Perkins et al. [46] showed that early decline in renal function was always associated with significantly increased IL-6, IL-8, monocyte chemoattractant, and other inflammatory markers in urine. In addition, many studies have found that TNFα is involved in the pathogenesis of diabetic nephropathy with albuminuria and that the Fas pathway mediating apoptosis may play a role in the progression of diabetic nephropathy [47– 49]. Niewczas et al. [50] observed 363 normoalbuminuria and 304 microalbuminuria patients with type 1 DM and showed that the concentration of serum TNFα (sTNFR1, sTNFR2) or Fas-pathways cytokines (sFasL and sFas) was associated with decreased eGFR independent of albuminuria. In the Cholesterol and Recurrent Events (CARE) study, serum TNF receptor 2 (sTNFR2) was found to be associated with the progression of kidney function loss [51]. Several studies have indicated that serum concentrations of TNF receptors (sTNFR1, sTNFR2) could be influenced by their upstream regulators, such as TNFα or IL1 and ADAM17 [52]. Many studies have shown that TNFα reduces glomerular blood flow directly and increases glomerular vasoconstriction, thus decreasing glomerular filtration rate [47]. This indicates that immune inflammation plays an important role in the decrease of renal function in NADKD. It is widely believed that renal function decline due to acute kidney injury (AKI) is transient and that renal impairment can be completely restored. However, recent clinical studies have shown that AKI can eventually result in chronic kidney disease as well, even though renal function has recovered [53]. Several mechanisms have been proposed for the progression of AKI to CKD, such as nephron loss, inflammation, endothelial injury with vascular rarefaction and hypoxia, epigenetic changes, and cell cycle arrest in epithelial cells [54–57]. DM is one of the important risk factors for the development of AKI [58–60]. Thakar et al. [61] conducted a longitudinal study observing 3679 DM patients and found that AKI was a risk factor for CKD (HR 3.56; 95% CI 2.76‒4.61) compared with DM patients without AKI, and the risk was independent of albuminuria. Onuigbo and colleagues [62] also reported that once AKI appeared in DM patients, renal function decline was more likely, and this was independent of urine protein levels. Therefore, we propose that AKI may be another important risk factor for renal function decrease in NADKD patients. Furthermore, the prevalence of NADKD varies across ethnic groups, suggesting that genetic susceptibility may be involved in the development of the disease. Polymorphism in the protein kinase C-b gene in DM patients is associated with eGFR decline [63]. Although there are a great number of studies on DKD susceptibility genes, the real causative genes or susceptibility genes involved in the pathogenesis and progression of NADKD have not yet been identified.

Advances in NADKD

Pathology of NADKD The observed pathological changes differ between NADKD and DKD with microalbuminuria or macroalbuminuria. Shimizu et al. [64] showed that NADKD patients have more severe renal pathological changes compared to patients with normal eGFR, including mesangial matrix proliferation, hyaline degeneration of renal arteries, and increased glomerular fibrosis [27,64]. Ekinci et al. [39] found that 3 in 8 NADKD patients showed typical glomerular changes, whereas the prevalence in patients with microalbuminuria and macroalbuminuria was 5/6 and 17/17. Yagil et al. [65] experimented on rat models (Cohen diabetic-resistant rats) and found that the pathological changes of Cohen diabetic-sensitive rats (an experimental model of type 2 diabetes mellitus that develops normoalbuminuric DKD) included mesangial matrix proliferation, thickened glomerular basement membrane, and increased type IV collagen in the glomeruli and interstitium. The renal pathological changes typical of NADKD are tubular and interstitial damage, but the mechanism of NADKD remains unclear.

Clinical features of NADKD Several studies mentioned above indicated that retinopathy is more frequent in albuminuric patients than in normoalbuminuric patients [21,24,32]. However, opinions on this matter differ. The prevalence of retinopathy in NADKD patients varies across studies. A study from RIACE with 2959 DKD patients with renal impairment found that 2028 (68.5%) patients had no retinopathy, 1280 (43.2%) NADKD patients had neither proteinuria nor retinopathy, and 538 patients (18.2%) showed both proteinuria and retinopathy [20]. The varying prevalence of retinopathy might be due to different observation methods, or it could be that the development of NADKD does not depend on microangiopathic lesions. Type 2 DM with albuminuria is an independent risk factor for cardiovascular disease (CVD), but the burden of CVD in NADKD is even higher [20]. For patients within the normoalbuminuria range (UAER < 30 mg/24h), the burden of CVD varies. In a cross-sectional analysis, normoalbuminuric patients were divided into normal albuminuria (NA) (UAER < 10 mg/24h) and low albuminuria (LA) (UAER 10–29 mg/24h) groups, and the burden of acute cardiovascular events, ulcers, coronary events, and peripheral vascular events was significantly higher in the LA group [66,67]. Therefore, NADKD patients should undergo quantitative detection of albuminuria, and those with UAER 10–29 mg/24h should receive vigilant follow-up for CVD events. As we can see from Fig. 1, the burden of diabetes complications in normoalbuminuric patients is lower than in DM patients with

Chao Chen et al.

5

DKD patients with proteinuria compared to NADKD patients. Rigalleau and colleagues [16] showed that NADKD patients had a lower risk for progression to ESRD than DM patients with proteinuria after 38 months of follow-up. This finding was consistent with what Boronat et al. [23] reported, possibly because normoalbuminuria alleviates eGFR decline [14]. A multi-center study found that among type 2 DM patients with renal dysfunction, all-cause mortality in the normoalbuminuric DKD group was not significantly lower compared to the proteinuric DKD group [69] and was higher when compared to the normal eGFR DKD group, suggesting that eGFR is a risk factor for death independent of proteinuria [64]. Therefore, monitoring renal function in NADKD patients is very important for predicting prognosis [21]. Fig. 1 Frequency of complications in the normoalbuminuria (UAER < 30 mg/24h) group, the microalbuminuria (UAER 30 300 mg/24h) group and the macroalbuminuria (UAER>300 mg/ 24h) group [19].

albuminuria. Boronat et al. [23] observed 78 DKD patients and found that in the normoalbuminuric group (21.8%), the BMI and waist circumference were significantly higher than in the microalbuminuria (20.5%) and macroalbuminuria (57.7%) groups. In addition, the average low-density lipoprotein (LDL) level was 1.02 mmol/L (90.4 mg/dl) in the NADKD group, compared to 0.85 mmol/L (75.1 mg/dl) in the control group. Another study found that NADKD is associated with higher hemoglobin levels. The risk factors associated with NADKD might include obesity, hyperlipidemia, and high hemoglobin. The clinical characteristics are summarized in Table 2. Perkins et al. [68] found that eGFR declined faster in

Diagnostic biomarkers of NADKD Neutrophil gelatinase-associated lipocalin (NGAL), a small protein that belongs to the lipocal superfamily, usually increases before the excretion of urine microalbumin in type 1 DM patients [70]. Some research also found that urine levels of NGAL increased progressively from ACR 10 mg/g creatinine to 30 mg/g creatinine in diabetic patients [71]. NGAL is now considered a reliable indicator of NADKD with high sensitivity and specificity [8]. Lim et al. [72] also found that zinc-α (2)-glycoprotein may be a urinary biomarker for NADKD. Moreover, several studies have indicated that liver-type fatty acid binding protein (L-FABP) and heart-type fatty acid binding protein (H-FABP) were important indicators of renal tubular injury, which can help in the diagnosis of NADKD [73,74].

Table 2 Characteristics of normoalbuminuric diabetic kidney disease Age (year)

MacIsaac et al. [7] 731

Female (%)

56%

Duration of diabetes 141 (year)

Kramer et al. [14] 62.910.3

Rigalleau et al. [16] Thomas et al. [19] 689 731

Ekinci et al. [39] 672.0

Shimizu et al. [64] 62.56.2

51%

66%

64%

62%

53%

10.17.0

145

91

122.4

7.46.4

BMI (kg/m2)

30.81

295.4

27.04.5

30.11

341.6

22.22.2

Smoking (%)

38%

11.4%

‒

29%

0

‒

HbA1c (%)

7.30.3

6.742.35

9.01.3

7.00.1

6.80.2

8.32.2

SBP (mmHg)

1383

14623.7

14316

1351

‒

12914.3

DBP (mmHg)

752

87.016.9

798

751

‒

75.610

TC (mmol/L)

4.40.2

5.761.3

2.370. 7

‒

4.40.2

‒

LDL-C (mmol/L)

2.60.1

3.691.1

1.260.5

2.40.1

‒

‒

HDL-C (mmol/L)

1.150.05

1.160.3

0.640.3

1.20.1

‒

‒

TG (mmol/L)

21.91.1

4.551.1

1.911.9

1.90.1

2.60.4

‒

Data are meanSEM; SPB, systolic blood pressure; DPB, diastolic blood pressure; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride.

6

Prevention of NADKD K/DOQI guidelines recommend that the diagnosis of DKD should be based on not only monitoring UAER and fundus changes but also assessment of eGFR [75]. The MDRD [76] or Cockcroft-Gault formula can be applied for the calculation of eGFR [77]. In addition, numerous studies have shown that the development of NADKD is closely related to gender, age, smoking, macrovascular disease, metabolic syndrome, and environmental factors [21,32]. Thus, female sex, old age, and metabolic syndrome are risk factors for NADKD. Regular monitoring of eGFR in highrisk patients could assist in timely diagnosis [78]. Currently, we do not have effective therapies for NADKD. It is generally believed that reducing urinary protein by controlling glucose, blood pressure, blood lipids, and other factors in DKD patients can protect renal function and especially delay the progression to chronic renal failure [79], but whether this is equally effective in NADKD patients remains to be shown [80,81]. Satirapoj et al. [82,83] showed that glycosaminoglycans (GAGs) could inhibit TGF-β1 transcription, which is induced by high levels of glucose, and protect against renal fibrosis in early-stage DM or DKD patients, but the efficacy in NADKD patients remains to be confirmed. Whether RAAS inhibitors can be used for NADKD treatment is also currently unclear. Dwyer et al. [84] proposed that RAAS inhibitors may play a protective role in NADKD progression by decreasing proteinuria, but more research is needed to confirm this.

Conclusions In short, DM patients with renal insufficiency (eGFR < 60 ml/(min$1.73 m2)) but urinary protein levels in the normal range and in whom other secondary kidney diseases (e.g., hypertensive nephropathy and obstructive nephropathy) are excluded should be considered as having DKD according to the latest ADA diagnostic criteria. Current clinical and basic research on such patients is lacking, and we need more multicenter, large-sample clinical research and investigations to further our understanding of NADKD.

Acknowledgements This study was sponsored by National Natural Science Foundation of China (Nos. 81470960, 81270812, 81570658, 81300600, and 81370832).

Compliance with ethics guidelines Chao Chen, Chang Wang, Chun Hu, Yachun Han, Li Zhao, Xuejing Zhu, Li Xiao, and Lin Sun declare that they have no conflict of

Advances in NADKD interest. This article does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

References 1. Xiao L, Wang M, Yang S, Liu F, Sun L.A glimpse of the pathogenetic mechanisms of Wnt/β-catenin signaling in diabetic nephropathy. Biomed Res Int 2013;2013:987064 2. Kwak SH, Park KS. Genetic studies on diabetic microvascular complications: focusing on genome-wide association studies. Endocrinol Metab (Seoul) 2015; 30(2): 147–158 3. Xu X, Xiao L, Xiao P, Yang S, Chen G, Liu F, Kanwar YS, Sun L. A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem 2014; 21(28): 3244–3260 4. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49(2 Suppl 2): S12–S154 5. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346(15): 1145–1151 6. Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, Jerums G. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994; 43 (5): 649–655 7. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27(1): 195–200 8. Lacquaniti A, Donato V, Pintaudi B, Di Vieste G, Chirico V, Buemi A, Di Benedetto A, Arena A, Buemi M. “Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL. Acta Diabetol 2013; 50(6): 935–942 9. Mottl AK, Kwon KS, Mauer M, Mayer-Davis EJ, Hogan SL, Kshirsagar AV. Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications 2013; 27(2): 123–127 10. MacIsaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 2011; 20(3): 246–257 11. American Diabetes Association. Standards of medical care in diabetes—2015 abridged for primary care providers. Clin Diabetes 2015; 33(2): 97–111 12. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20(4): 516–519 13. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND study. Cardiorenal Med 2012; 2(1): 1–10 14. Kramer CK, Leitão CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 2007; 30(8): 1998–2000 15. Bhalla V, Zhao B, Azar KM, Wang EJ, Choi S, Wong EC, Fortmann SP, Palaniappan LP. Racial/ethnic differences in the prevalence of proteinuric and nonproteinuric diabetic kidney disease. Diabetes Care 2013; 36(5): 1215–1221

Chao Chen et al. 16. Rigalleau V, Lasseur C, Raffaitin C, Beauvieux MC, Barthe N, Chauveau P, Combe C, Gin H. Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group. Diabetes Care 2007; 30(8): 2034–2039 17. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55(6): 1832– 1839 18. Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M; Japan Diabetes Clinical Data Management Study Group. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009; 24 (4): 1212–1219 19. Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 2009; 32(8): 1497–1502 20. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011; 29(9): 1802–1809 21. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289(24): 3273–3277 22. New JP, Middleton RJ, Klebe B, Farmer CK, de Lusignan S, Stevens PE, O’Donoghue DJ. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet Med 2007; 24(4): 364–369 23. Boronat M, García-Cantón C, Quevedo V, Lorenzo DL, López-Ríos L, Batista F, Riaño M, Saavedra P, Checa MD. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail 2014; 36 (2): 166–170 24. Penno G, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, Gruden G, Cavalot F, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care 2012; 35(11): 2317–2323 25. Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, Zinman B, Lachin J; Epidemiology of Diabetes Interventions and Complications Study Group. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33(7): 1536–1543 26. Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005; 54(10): 2983–2987

7 27. Lane PH, Steffes MW, Mauer SM. Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes 1992; 41(5): 581–586 28. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000; 11(2): 319–329 29. Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries AP; ERA-EDTA diabesity working group. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol 2015; 3 (5): 382–391 30. Diamond-Stanic MK, You YH, Sharma K. Sugar, sex, and TGF-β in diabetic nephropathy. Semin Nephrol 2012; 32(3): 261–268 31. Ahmed SB, Culleton BF, Tonelli M, Klarenbach SW, Macrae JM, Zhang J, Hemmelgarn BR; Alberta Kidney Disease Network. Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int 2008; 74(3): 370–376 32. An JH, Cho YM, Yu HG, Jang HC, Park KS, Kim SY, Lee HK. The clinical characteristics of normoalbuminuric renal insufficiency in Korean type 2 diabetic patients: a possible early stage renal complication. J Korean Med Sci 2009; 24(Suppl): S75–S81 33. Shimizu M, Furuichi K, Yokoyama H, Toyama T, Iwata Y, Sakai N, Kaneko S, Wada T. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin Exp Nephrol 2014; 18 (2): 305–312 34. Taniwaki H, Nishizawa Y, Kawagishi T, Ishimura E, Emoto M, Okamura T, Okuno Y, Morii H. Decrease in glomerular filtration rate in Japanese patients with type 2 diabetes is linked to atherosclerosis. Diabetes Care 1998; 21(11): 1848–1855 35. MacIsaac RJ, Panagiotopoulos S, McNeil KJ, Smith TJ, Tsalamandris C, Hao H, Matthews PG, Thomas MC, Power DA, Jerums G. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 2006; 29(7): 1560–1566 36. Boeri D, Derchi LE, Martinoli C, Simoni G, Sampietro L, Storace D, Ponte L, Calvi C, Repetto M, Robaudo C, Maiello M. Intrarenal arteriosclerosis and impairment of kidney function in NIDDM subjects. Diabetologia 1998; 41(1): 121–124 37. Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, Fitzgerald AP, Sandhu B, Jackson PG. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes 1998; 47(11): 1786–1792 38. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38(5): 604–609 39. Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, Panagiotopoulos S, McNeil K, Baker ST, Fioretto P, Macisaac RJ. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care 2013; 36 (11): 3620–3626 40. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351(19): 1941–1951 41. Border WA, Yamamoto T, Noble NA. Transforming growth factor β

8 in diabetic nephropathy. Diabetes Metab Rev 1996; 12(4): 309–339 42. Bader R, Bader H, Grund KE, Mackensen-Haen S, Christ H, Bohle A. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters. Pathol Res Pract 1980; 167(2-4): 204–216 43. Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 1993; 43(3): 661–667 44. Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43(8): 1046–1051 45. Sun L, Kanwar YS. Relevance of TNF-α in the context of other inflammatory cytokines in the progression of diabetic nephropathy. Kidney Int 2015; 88(4): 662–665 46. Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 2009; 18(3): 233–240 47. Navarro JF, Mora-Fernández C. The role of TNF-α in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006; 17(6): 441–450 48. Schelling JR, Nkemere N, Kopp JB, Cleveland RP. Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 1998; 78(7): 813–824 49. Perianayagam MC, Murray SL, Balakrishnan VS, Guo D, King AJ, Pereira BJ, Jaber BL. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure. J Lab Clin Med 2000; 136(4): 320–327 50. Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, Warram JH, Krolewski AS. Serum concentrations of markers of TNFα and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009; 4(1): 62–70 51. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68(1): 237–245 52. Bell JH, Herrera AH, Li Y, Walcheck B. Role of ADAM17 in the ectodomain shedding of TNF-α and its receptors by neutrophils and macrophages. J Leukoc Biol 2007; 82(1): 173–176 53. Onuigbo MA. Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRD. Ren Fail 2010; 32(8): 954–958 54. Ascon M, Ascon DB, Liu M, Cheadle C, Sarkar C, Racusen L, Hassoun HT, Rabb H. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int 2009; 75(5): 526–535 55. Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Compr Physiol 2012; 2(2): 1303–1353 56. Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 2001; 281(5): F887–F899 57. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 2012; 82(5): 516–524 58. Zhao Z, Zhu B, Anderson J, Fu H, LeNarz L. Resource utilization and healthcare costs for acute coronary syndrome patients with and

Advances in NADKD without diabetes mellitus. J Med Econ 2010; 13(4): 748–759 59. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296–1305 60. Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 2008; 3(3): 844–861 61. Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 2011; 6(11): 2567–2572 62. Onuigbo MA, Agbasi N. Diabetic nephropathy and CKD-analysis of individual patient serum creatinine trajectories: a forgotten diagnostic methodology for diabetic CKD prognostication and prediction. J Clin Med 2015; 4(7): 1348–1368 63. Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D. Polymorphisms of the protein kinase C-β gene (PRKCB1) accelerate kidney disease in type 2 diabetes without overt proteinuria. Diabetes Care 2006; 29(4): 864–868 64. Shimizu M, Furuichi K, Toyama T, Kitajima S, Hara A, Kitagawa K, Iwata Y, Sakai N, Takamura T, Yoshimura M, Yokoyama H, Kaneko S, Wada T; Kanazawa Study Group for Renal Diseases and Hypertension.Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care 2013; 36(11): 3655–3662 65. Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, Segev Y, Weksler-Zangen S, Raz I, Yagil Y. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes 2005; 54(5): 1487–1496 66. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54(2): 205–226 67. Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Laviola L, Orsi E, Pugliese G; Renal Insufficiency Cardiovascular Events (RIACE) Study Group. Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Acta Diabetol 2015; 52(5): 971–981 68. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, Krolewski AS. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18(4): 1353–1361 69. De Cosmo S, Lamacchia O, Pacilli A, Fariello S, Pinnelli S, Fontana A, Di Mauro L, Cignarelli M, Trischitta V. Normoalbuminuric renal impairment and all-cause mortality in type 2 diabetes mellitus. Acta Diabetol 2014; 51(4): 687–689 70. Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR, Parving HH, Rossing P. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 2010; 27(10): 1144–1150 71. de Carvalho JA, Tatsch E, Hausen BS, Bollick YS, Moretto MB, Duarte T, Duarte MM, Londero SW, Premaor MO, Comim FV, Delanghe JR, Moresco RN. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular

Chao Chen et al.

72.

73.

74.

75.

76.

77.

damage in normoalbuminuric patients with type 2 diabetes. Clin Biochem 2016; 49(3): 232–236 Lim SC, Liying DQ, Toy WC, Wong M, Yeoh LY, Tan C, Lau D, Tan C, Subramaniam T, Sum CF. Adipocytokine zinc α2 glycoprotein (ZAG) as a novel urinary biomarker for normoalbuminuric diabetic nephropathy. Diabet Med 2012; 29(7): 945– 949 Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, Kaise R, Ishimitsu T, Tanaka Y, Kimura K. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 2011; 34(3): 691–696 Alter ML, Kretschmer A, Von Websky K, Tsuprykov O, Reichetzeder C, Simon A, Stasch JP, Hocher B. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab 2012; 58(7-8): 659–671 National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1–S266 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130(6): 461–470 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41

9 78. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52(4): 1036–1040 79. Van Buren PN, Toto R. Current update in the management of diabetic nephropathy. Curr Diabetes Rev 2013; 9(1): 62–77 80. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861–869 81. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–860 82. Satirapoj B, Kaewput W, Supasyndh O, Ruangkanchanasetr P. Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial. J Diabetes Res 2015; 2015:172038 83. Nielsen SE, Reinhard H, Zdunek D, Hess G, Gutiérrez OM, Wolf M, Parving HH, Jacobsen PK, Rossing P. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 2012; 97(1): 71–76 84. Dwyer JP, Lewis JB. Nonproteinuric diabetic nephropathy: when diabetics don’t read the textbook. Med Clin North Am 2013; 97(1): 53–58